ClinicalTrials.gg
CompletedNCT05956405Updated Sep 16, 2025

Retraining of the Amygdala and Insula for the Treatment of Persistent Covid

An interventional study of AIR + Mindfulness and Relaxation condition in Mental Health Wellness, sponsored by Hospital Miguel Servet. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Hospital Miguel Servet · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Prolonged COVID, also known as post-COVID or Sar-CoV-2 infection with post-acute sequelae, refers to a set of multi-organ symptoms that persist in patients who have suffered SARS-CoV-2 infection, even after of the acute phase of the disease. Approximately 10% of people experience this set of symptoms after their acute COVID has resolved. Such symptoms may include respiratory problems, myalgia, extreme fatigue, moodiness, cognitive impairment, and difficulty sleeping.

Psychological therapies, such as mindfulness, have already demonstrated their effectiveness in pathologies of this type, improving mental health and physical function, as well as reinforcing acceptance and reducing symptoms. Specifically, amygdala-insula training was originally designed for patients with chronic fatigue syndrome as a method of reducing chronic over-sensitization and heightened fear response of the amygdala, which may be behind some of the symptoms related to both with this pathology as with fibromyalgia.

A lot of research is currently being done on different types of treatments such as pharmaceutical, biological, dietary, homeopathic and rehabilitation for the treatment of persistent COVID; however, an effective treatment has not yet been found. Therefore, this study aims to evaluate the impact of a retraining intervention of the amygdala and insula for the improvement of the quality of life of patients with persistent COVID.

02

Conditions studied

  • Mental Health Wellness
03

In context

Lead sponsor

Hospital Miguel Servet is the lead sponsor of 25 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-30 years old.
  • Grant .
  • Diagnosis of persistent COVID by primary care physicians.

Exclusion criteria

Exclusion Criteria:

  • Age: \<18 years old
  • Serious medical or psychiatric illnesses
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Amygdala & Insula Retraining + Mindfulness

    Behavioral: AIR + Mindfulness

  • Active comparator
    Relaxation condition

    Behavioral: Relaxation condition

Interventions

  • BehavioralAIR + Mindfulness

    AIR + Mindfulness program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.

  • BehavioralRelaxation condition

    Relaxation program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.

06

What researchers measure

Primary outcomes

  1. Short Form de 36 items (SF-36)

    In the AIR + Mindfulness program group

    Time frame: Baseline

  2. Short Form de 36 items (SF-36)

    In the AIR + Mindfulness program group

    Time frame: Post-treatment 8 weeks from baseline

  3. Short Form de 36 items (SF-36)

    In the AIR + Mindfulness program group

    Time frame: Three-months follow-up

  4. Short Form de 36 items (SF-36)

    In the relaxation program group

    Time frame: Baseline

  5. Short Form de 36 items (SF-36)

    In the relaxation program group

    Time frame: Post-treatment 8 weeks from baseline

  6. Short Form de 36 items (SF-36)

    In the relaxation program group

    Time frame: Three-months follow-up

Secondary outcomes

  1. Sociodemographic data Gender, age, marital status, education, occupation, economical level

    In the AIR + Mindfulness program group

    Time frame: Baseline

  2. Sociodemographic data Gender, age, marital status, education, occupation, economical level

    In the relaxation program group

    Time frame: Baseline

  3. Spanish Chronic Pain Grading Scale

    In the AIR + Mindfulness program group

    Time frame: Baseline

  4. Spanish Chronic Pain Grading Scale

    In the relaxation program group

    Time frame: Baseline

  5. Spanish Chronic Pain Grading Scale

    In the AIR + Mindfulness program group

    Time frame: Post-treatment 8 weeks from baseline

  6. Spanish Chronic Pain Grading Scale

    In the relaxation program group

    Time frame: Post-treatment 8 weeks from baseline

  7. Spanish Chronic Pain Grading Scale

    In the AIR + Mindfulness program group

    Time frame: Three-months follow-up

  8. Spanish Chronic Pain Grading Scale

    In the relaxation program group

    Time frame: Three-months follow-up

  9. Pain Catastrophizing Scale (PCS)

    In the AIR + Mindfulness program group

    Time frame: Baseline

  10. Pain Catastrophizing Scale (PCS)

    In the relaxation program group

    Time frame: Baseline

  11. Pain Catastrophizing Scale (PCS)

    In the AIR + Mindfulness program group

    Time frame: Post-treatment 8 weeks from baseline

  12. Pain Catastrophizing Scale (PCS)

    In the relaxation program group

    Time frame: Post-treatment 8 weeks from baseline

  13. Pain Catastrophizing Scale (PCS)

    In the AIR + Mindfulness program group

    Time frame: Three-months follow-up

  14. Pain Catastrophizing Scale (PCS)

    In the relaxation program group

    Time frame: Three-months follow-up

  15. Modified Fatigue Impact Scale (MFIS)

    In the AIR + Mindfulness program group

    Time frame: Baseline

  16. Modified Fatigue Impact Scale (MFIS)

    In the relaxation program group

    Time frame: Baseline

  17. Modified Fatigue Impact Scale (MFIS)

    In the AIR + Mindfulness program group

    Time frame: Post-treatment 8 weeks from baseline

  18. Modified Fatigue Impact Scale (MFIS)

    In the relaxation program group

    Time frame: Post-treatment 8 weeks from baseline

  19. Modified Fatigue Impact Scale (MFIS)

    In the AIR + Mindfulness program group

    Time frame: Three-months follow-up

  20. Modified Fatigue Impact Scale (MFIS)

    In the relaxation program group

    Time frame: Three-months follow-up

  21. Insomnia Severity Index (ISI)

    In the AIR + Mindfulness program group

    Time frame: Baseline

  22. Insomnia Severity Index (ISI)

    In the relaxation program group

    Time frame: Baseline

  23. Insomnia Severity Index (ISI)

    In the AIR + Mindfulness program group

    Time frame: Post-treatment 8 weeks from baseline

  24. Insomnia Severity Index (ISI)

    In the relaxation program group

    Time frame: Post-treatment 8 weeks from baseline

  25. Insomnia Severity Index (ISI)

    In the AIR + Mindfulness program group

    Time frame: Three-months follow-up

  26. Insomnia Severity Index (ISI)

    In the relaxation program group

    Time frame: Three-months follow-up

  27. General Anxiety Disorder-7 (GAD-7)

    In the AIR + Mindfulness program group

    Time frame: Baseline

  28. General Anxiety Disorder-7 (GAD-7)

    In the relaxation program group

    Time frame: Baseline

  29. General Anxiety Disorder-7 (GAD-7)

    In the AIR + Mindfulness program group

    Time frame: Post-treatment 8 weeks from baseline

  30. General Anxiety Disorder-7 (GAD-7)

    In the relaxation program group

    Time frame: Post-treatment 8 weeks from baseline

  31. General Anxiety Disorder-7 (GAD-7)

    In the AIR + Mindfulness program group

    Time frame: Three-months follow-up

  32. General Anxiety Disorder-7 (GAD-7)

    In the relaxation program group

    Time frame: Three-months follow-up

  33. Patient Health Questionnaire (PHQ-9)

    In the AIR + Mindfulness program group

    Time frame: Baseline

  34. Patient Health Questionnaire (PHQ-9)

    In the relaxation program group

    Time frame: Baseline

  35. Patient Health Questionnaire (PHQ-9)

    In the AIR + Mindfulness program group

    Time frame: Post-treatment 8 weeks from baseline

  36. Patient Health Questionnaire (PHQ-9)

    In the relaxation program group

    Time frame: Post-treatment 8 weeks from baseline

  37. Patient Health Questionnaire (PHQ-9)

    In the AIR + Mindfulness program group

    Time frame: Three-months follow-up

  38. Patient Health Questionnaire (PHQ-9)

    In the relaxation program group

    Time frame: Three-months follow-up

  39. Memory failures of Everyday (MFE)

    In the AIR + Mindfulness program group

    Time frame: Baseline

  40. Memory failures of Everyday (MFE)

    In the relaxation program group

    Time frame: Baseline

  41. Memory failures of Everyday (MFE)

    In the AIR + Mindfulness program group

    Time frame: Post-treatment 8 weeks from baseline

  42. Memory failures of Everyday (MFE)

    In the relaxation program group

    Time frame: Post-treatment 8 weeks from baseline

  43. Memory failures of Everyday (MFE)

    In the AIR + Mindfulness program group

    Time frame: Three-months follow-up

  44. Memory failures of Everyday (MFE)

    In the relaxation program group

    Time frame: Three-months follow-up

  45. Five Facets of Mindfulness Questionnaire (FFMQ)

    In the AIR + Mindfulness program group

    Time frame: Baseline

  46. Five Facets of Mindfulness Questionnaire (FFMQ)

    In the relaxation program group

    Time frame: Baseline

  47. Five Facets of Mindfulness Questionnaire (FFMQ)

    In the AIR + Mindfulness program group

    Time frame: Post-treatment 8 weeks from baseline

  48. Five Facets of Mindfulness Questionnaire (FFMQ)

    In the relaxation program group

    Time frame: Post-treatment 8 weeks from baseline

  49. Five Facets of Mindfulness Questionnaire (FFMQ)

    In the AIR + Mindfulness program group

    Time frame: Three-months follow-up

  50. Five Facets of Mindfulness Questionnaire (FFMQ)

    In the relaxation program group

    Time frame: Three-months follow-up

  51. Emotional Regulation Questionnaire (ERQ)

    In the AIR + Mindfulness program group

    Time frame: Baseline

  52. Emotional Regulation Questionnaire (ERQ)

    In the relaxation program group

    Time frame: Baseline

  53. Emotional Regulation Questionnaire (ERQ)

    In the AIR + Mindfulness program group

    Time frame: Post-treatment 8 weeks from baseline

  54. Emotional Regulation Questionnaire (ERQ)

    In the relaxation program group

    Time frame: Post-treatment 8 weeks from baseline

  55. Emotional Regulation Questionnaire (ERQ)

    In the AIR + Mindfulness program group

    Time frame: Three-months follow-up

  56. Emotional Regulation Questionnaire (ERQ)

    In the relaxation program group

    Time frame: Three-months follow-up

  57. Acceptance and Action Questionnaire-II (AAQ-II)

    In the AIR + Mindfulness program group

    Time frame: Baseline

  58. Acceptance and Action Questionnaire-II (AAQ-II)

    In the relaxation program group

    Time frame: Baseline

  59. Acceptance and Action Questionnaire-II (AAQ-II)

    In the AIR + Mindfulness program group

    Time frame: Post-treatment 8 weeks from baseline

  60. Acceptance and Action Questionnaire-II (AAQ-II)

    In the relaxation program group

    Time frame: Post-treatment 8 weeks from baseline

  61. Acceptance and Action Questionnaire-II (AAQ-II)

    In the AIR + Mindfulness program group

    Time frame: Three-months follow-up

  62. Acceptance and Action Questionnaire-II (AAQ-II)

    In the AIR + Mindfulness program group

    Time frame: In the relaxation program group

07

Study locations

1 site
  • Department of Psychiatry. Miguel Servet University Hospital
    Zaragoza, 50009, Spain
08

References and documents

Publications

  • Gasion V, Barcelo-Soler A, Beltran-Ruiz M, Hijar-Aguinaga R, Camarero-Grados L, Lopez-Del-Hoyo Y, Garcia-Campayo J, Montero-Marin J. Effectiveness of an amygdala and insula retraining program combined with mindfulness training to improve the quality of life in patients with long COVID: a randomized controlled trial protocol. BMC Complement Med Ther. 2023 Nov 9;23(1):403. doi: 10.1186/s12906-023-04240-0. PubMed 37946190 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Mar 2024, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2023
First posted
Jul 21, 2023
StartActual
Sep 1, 2023
Primary completionActual
Mar 31, 2024
CompletionActual
Mar 31, 2024
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05956405
Lead sponsor
Hospital Miguel Servet
Responsible party
Javier Garcia Campayo (Principal Investigator, Hospital Miguel Servet) — Principal investigator
First posted
Jul 21, 2023
Start date
Sep 1, 2023
Primary completion
Mar 31, 2024
Completion
Mar 31, 2024
Last update
Sep 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion